RxDoctor Payments Data

Anthony Perry, DO

Internal Medicine · Massillon, OHNPI 1619976313

Payments from drug & device makers

$7,293in general payments, 2019–2025

Across 489 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$839
  • Lilly USA, LLC$482
  • AbbVie$465
  • Pfizer$424
  • Johnson & Johnson$412
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$7,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,293 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$82,924
Medicare patients
207
Services billed
863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban367$157,714
JardianceEmpagliflozin177$103,492
JanuviaSitagliptin Phosphate102$66,699
XareltoRivaroxaban75$41,547
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$26,521
MyrbetriqMirabegron88$19,793
FarxigaDapagliflozin Propanediol33$19,060
TrulicityDulaglutide17$18,619
VraylarCariprazine Hcl25$17,915
EntrestoSacubitril/Valsartan29$15,911
LinzessLinaclotide21$11,846
OzempicSemaglutide12$11,093
Atorvastatin Calcium825$10,216
Potassium Chloride290$9,264
Spiriva RespimatTiotropium Bromide11$8,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$424$157,714367 claims
Boehringer IngelheimJardiance, Spiriva Respimat$380$112,395188 claims
MerckJanuvia$298$66,699102 claims
Johnson & JohnsonXarelto$412$41,54775 claims
GSKTrelegy Ellipta, Breo Ellipta$127$33,10842 claims
AbbVieVraylar, Linzess$465$29,76146 claims
AstraZenecaFarxiga, Symbicort$1,071$24,94151 claims
Astellas Pharma US IncMyrbetriq$86$19,79388 claims
Lilly USA, LLCTrulicity$482$18,61917 claims
NovartisEntresto$298$15,91129 claims
Novo NordiskOzempic, Fiasp$839$15,74727 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant$57$12,76244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Massillon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →